Predict your next investment

HEALTHCARE | Biotechnology
appharma.com

See what CB Insights has to offer

Founded Year

1983

Stage

Unattributed VC | Alive

Total Raised

$12.46M

Last Raised

$12.46M | 17 yrs ago

About AP Pharma

A.P. Pharma is a specialty pharmaceutical company focused on the development of ethical (prescription) pharmaceuticals utilizing its proprietary polymer-based drug delivery systems. The Company's primary focus is the development and commercialization of its bioerodible injectable and implantable systems under the trade name Biochronomer(TM). Initial target areas of application for the Company's drug delivery technology include anti-nausea, pain management, anti-inflammation and DNA/RNAI applications. For further information visit the Company's web site at www.appharma.com.

AP Pharma Headquarter Location

123 Saginaw Drive

Redwood City, California, 94063,

United States

650-366-2626

Latest AP Pharma News

Stocks on the Move: Augme Technologies Inc., AP Pharma Inc., Lone Star Gold Inc., China Logistics Group Inc.

Jan 10, 2013

Jan 10, 2013, 09:00 ET from Equities Awareness Group LLC NEW YORK, January 10, 2013 /PRNewswire/ -- PremierEquityReports.com provides investors with quality research and analysis on U.S. equities on the move and today issues a report on: Augme Technologies Inc. (OTCBB: AUGT), AP Pharma Inc. (OTCBB: APPA), Lone Star Gold Inc. (OTCBB: LSTG), and China Logistics Group Inc. (OTCBB: CHLO) Augme Technologies Inc. (OTCBB: AUGT) shares got pummeled on January 9th falling about -30%. This drop comes on the back of Augme Technologies announcing positive third quarter fiscal results. Augme reported revenue totaling $7.4 million compared to $6.2 million for the second quarter of fiscal 2013 and $4.4 million for the third quarter of fiscal 2012. Read the entire press release issued by Augme Technologies Inc. (OTCBB: AUGT) here: http://finance.yahoo.com/news/augme-technologies-inc-reports-third-130000508.html   AP Pharma Inc. (OTCBB: APPA) has gained 38% in the last seven trading days hitting a high of $0.72. AP Pharma has not issued a significant press release during that time. AP Pharma's 52-week high is $0.78. Lone Star Gold Inc. (OTCBB: LSTG) announced its $15 million common-stock purchase investment agreement with Deer Valley Management LLC is now effective. The Company plans to commence on-site processing plant construction. The processing plant will further enhance Lone Star's ability to maximize the silver and gold content per ton of shipment from the project's 1.2 million tons of mine tailings. The Company expects the on-site processing plant to be operational in 3-4 months. Read the entire press release issued by Lone Star Gold Inc. (OTCBB: LSTG) here: http://finance.yahoo.com/news/lone-star-gold-inc-announces-162447561.html China Logistics Group Inc. (OTCBB: CHLO) has been the most volatile stock on any publically traded exchange this week. China Logistics opened for trade on Monday, January 7th, at $0.0056 and hit a high of $0.168 on January 9th making for more than a 6,100% gain from January 4th's closing price of $0.0027. China Logistics' extreme volatility is evident in the fact that it closed at $0.067 on January 9th finishing down -44.12% after hitting an intraday high of $0.168. Sign up to receive detailed reports and stock picks at http://www.PremierEquityReports.com . For real-time trade updates, follow our award winning hedge fund trader on Twitter @StockBrainiac. Premier Equity Reports also offers a FREE text message alert service to ensure that you receive all alerts. Simply text "reports" to 63566. Premier Equity Reports is the U.S. leader in equity reports, offering quality reports to investors looking for the most undervalued companies in the market. Premier Equity Reports provides its subscribers with timely information and exclusive analysis on U.S. companies with substantial upside potential. Premier Equity Reports is the #1 free financial newsletter in the industry. Sign up now and see why thousands have joined already. Disclosure: PremierEquityReports.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Premier Equity Reports is a wholly owned entity of Equities Awareness Group LLC. Equities Awareness Group LLC has not been compensated by any of the companies mentioned above. Please read our report and visit our website, for complete risks and disclosures. Contact Information:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing AP Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

AP Pharma is included in 1 Expert Collection, including Biopharmaceuticals.

B

Biopharmaceuticals

5,882 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

AP Pharma Patents

AP Pharma has filed 6 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/24/2011

8/28/2012

Excipients, Progestogens, Dosage forms, Androgens and anabolic steroids, Drug delivery devices

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

10/24/2011

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

8/28/2012

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Excipients, Progestogens, Dosage forms, Androgens and anabolic steroids, Drug delivery devices

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.